Orexo to Present at the Annual Biotech Showcase Conference, San Francisco
Uppsala, Sweden, December 19, 2016 – Orexo AB (publ.), announced today that it will present at the 9th Annual Biotech Showcase Conference being held January 9-11, 2017 in San Francisco, CA.
Nikolaj Sørensen, President and CEO of Orexo AB, will present the business, focusing on the driving forces behind the global opioid addiction treatment market, the development of Zubsolv® in the US and the progress towards launching in the rest of the world. An overview will also be given of Orexo’s pipeline of innovative product development programs and the company’s recent strong financial development.
|Event:||9th Annual Biotech Showcase Conference|
|Date:||Monday, January 9, 2017|
|Time:||11:00 am (Pacific Time)|
|Location:||Room 3 (Ballroom Level), Parc 55 Hotel, San Francisco, CA|
If you would like to get an update about Orexo today please visit www.orexo.com for the most recent investor presentations, financial reports and our investor dialogue. In addition a fresh interview with Nikolaj Sørensen is available at www.orexo.com.
For more information please contact:
|Orexo AB (publ.)|
|Lena Wange, IR & Communications Manager||Tirth Patel, Edison Advisors|
|Tel: +46 18 780 88 00||Tel: +1 646 653 7035|
|Email: email@example.com||Email: firstname.lastname@example.org|
Orexo is a specialty pharmaceutical company commercializing its proprietary product Zubsolv® for treatment of opioid dependence in the US. Zubsolv is an advanced formulation of buprenorphine and naloxone using Orexo’s unique knowledge and expertise in sublingual drug delivery. R&D is focusing on reformulation of known substances to new improved products that meet great unmet medical needs by using its patented proprietary technologies. Orexo’s share is listed on Nasdaq Stockholm Exchange Mid Cap (STO:ORX) and is available as ADRs on OTCQX (ORXOY) in the US. Orexo’s global headquarters and R&D are based in Uppsala, Sweden.
For more information about Orexo, please visit www.orexo.com or follow us on Twitter or LinkedIn.
For further information about Zubsolv in the US, please visit www.zubsolv.com.
The information was submitted for publication at 4:15pm CET, December 19, 2016